Why the study?
Does prophylactic anticoagulation reduce thromboembolic events and improve survival in patients with pancreas cancer?
Does prophylactic anticoagulation reduce thromboembolic events and improve survival in patients with pancreas cancer?
While prophylactic anticoagulation effectively reduces the high risk of thromboembolic events in patients with pancreas cancer, its potential to improve overall survival remains uncertain and warrants further investigation.
Prophylactic anticoagulation may warrant consideration for thrombosis prevention in pancreas cancer; leaves open survival benefit pending definitive RCTs.
Exocrine pancreas cancer continues to represent a significant therapeutic challenge, with high rates of mortality and morbidity, including from thromboembolic events, which have long been described as a frequent complication of the disease. This article provides a systematic and comprehensive review of the literature to address the clinical and pathologic features recognized in pancreas cancer pertaining to thrombosis, and to discuss ongoing investigations of prophylactic anticoagulation in the hopes of improving disease-related outcomes.
No takes yet. Share an insight, caveat, or question.
Epstein et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: